Niclosan

Quick links to important sections

Niclosan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Niclosan

Quick Facts

Property Description
Active ingredient Niclosamide
Form Oral tablet (often chewable)
Pharmacological class Anthelmintic (Cestocidal agent)
Common use Elimination of parasitic tapeworms
Origin Synthetic (salicylanilide derivative)

Identity and Pharmacological Classification

Niclosan is a pharmaceutical product primarily containing the active ingredient Niclosamide. It is formally classified as a synthetic Anthelmintic drug, meaning its core function is the treatment of infections caused by parasitic worms. Specifically, it operates as a Cestocidal agent, focused on targeting and neutralizing tapeworms (Cestodes). This focused efficacy is recognized for its reliability in treating cestode infestations.

Niclosamide is regarded as a fundamental medication in global healthcare, serving as a necessary and effective treatment for these specific parasitic infections.

Composition, Origin, and General Purpose

The medication is a pure, single-ingredient product. Niclosamide belongs to the salicylanilide derivative chemical class. It is a synthetic compound with a known and stable chemical structure.

Niclosan is administered via the oral route, commonly prepared as a standard or chewable tablet. This particular oral form simplifies administration. Its general purpose is the neutralization and elimination of tapeworm parasites from the body, offering a solution for patients diagnosed with these specific intestinal infestations. The drug acts locally within the gastrointestinal tract, ensuring the inert parasite is rendered non-viable and can be expelled.

What side effects are possible with Niclosan?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Niclosan (Niclosamide) primarily into frequency tiers based on clinical data, with effects largely localized to the gastrointestinal system, consistent with its action as a locally acting anthelmintic agent.

Official Side Effects and Frequency Classification

Adverse reactions are documented across two primary frequency tiers in labeling based on clinical experience:

Frequency Classification Associated Adverse Reactions
Less Common Abdominal or stomach cramps or pain, diarrhea, loss of appetite, nausea or vomiting.
Rare Dizziness or lightheadedness, drowsiness, itching of the rectal area, skin rash, unpleasant taste.

No adverse reactions are explicitly designated as Serious Adverse Reactions in the available official regulatory documentation.

Population-Specific Safety Considerations

Official labels address specific populations, maintaining a safety focus without providing instruction:

  • Pediatric Population: Studied in children aged two years and older. The medicine has not been reported to cause different side effects or problems in children compared to adults.
  • Breastfeeding: Available studies suggest a minimal risk to the infant when Niclosamide is used during breastfeeding.
  • Safety Restrictions: A history of unusual or allergic reactions to Niclosamide or its components is a necessary safety consideration documented in the prescribing information.

The regulatory safety structure is defined by these less common and rare effects, primarily affecting the digestive system, which helps structure the overall understanding of the medicine's risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the official regulatory profile for Niclosan (Niclosamide) overdose, which is based on the drug's limited systemic absorption.

Official Regulatory Profile Summary

Classification Official Regulatory Finding
Expected Toxicity Toxic effects are not expected due to the active substance being only slightly absorbed from the gastrointestinal tract.
Severe Manifestations No specific severe or life-threatening outcomes are formally documented in official labeling.
Antidote Availability There is no specific antidote for Niclosamide documented in regulatory information.

Required Emergency Actions

Regulatory documents mandate specific procedural steps should a marked overdosage be suspected, as an overdose is not predicted to cause severe symptoms.

  • When to seek help: Immediate medical attention must be sought in the event of a marked overdosage. This action is required even though systemic toxicity is not expected.
  • Required management: The official instruction is to apply the usual therapeutic measures for the treatment of poisoning. This includes supportive and symptomatic therapy to manage any non-specific symptoms that may arise.

The low risk of systemic toxicity in an overdose is directly linked to the drug's poor absorption, as documented by official government health authorities.

Therapeutic Uses of Niclosan

Managing Symptom Clusters in Parasitic Conditions

Niclosan (Niclosamide) is used in situations involving certain distressing symptoms associated with tapeworm infestations. It is categorized as an anthelmintic agent. The medication is commonly used across conditions presenting with acute or disruptive episodes, and is relevant for infections that cause significant symptomatic burden. It is used to address symptom clusters that may become intense or disruptive, like gastrointestinal discomfort and associated symptoms that interfere with daily comfort. Niclosan provides a supportive role for managing difficult episodes.


Easing Discomfort and Functional Strain

The medicine is applied across domains where additional symptomatic support is needed to address the overall burden. It is relevant in contexts marked by increased discomfort or tension from conditions involving episodic or fluctuating manifestations. Niclosan assists with managing symptoms related to systemic imbalance and temporary functional strain. This contributes to day-to-day comfort during periods of heightened symptoms, supporting general well-being during symptomatic phases.

“Applied in areas where short-term symptom management is appropriate.”

Quick Fact: May provide support for gastrointestinal discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Niclosan

This information is based on official regulatory documents describing eligibility and contraindications for Niclosan (niclosamide).


Contraindications and Restricted Use

Classification Populations
Contraindicated Patients with a known hypersensitivity or allergy to Niclosamide or any of its formulation ingredients.
Use Restricted Patients with asthma (listed as a contraindication in some regulatory sources).

Established and Special Consideration Populations

Population Group Official Eligibility Status
Age (Pediatric) Use is established for children aged 2 years and older. Dosing guidelines are provided for children based on age and weight. Use in those under 2 years requires special consideration due to limited data.
Age (Geriatric) No specific information is available comparing its use in the elderly versus younger adults.
Hepatic/Renal Impairment May be given safely as the drug is minimally absorbed; however, dose adjustments may be required due to the potential for altered metabolism or excretion.
Pregnancy/Lactation Generally considered to have no formal contraindication. Studies suggest minimal risk to the breastfed infant due to poor oral absorption.

The regulatory profile primarily defines who should not take the drug based on allergic status. Otherwise, use is established across a broad range of adults and children aged two years and up, with specific circumstances like hepatic or renal impairment necessitating professional judgment regarding dosage.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Niclosan (Niclosamide) is highly specific and is primarily defined by the drug's limited systemic absorption following oral administration. Regulatory summaries do not explicitly list numerous systemic drug–drug interactions involving metabolic pathways or transporters, a finding consistent with its local action as an anthelmintic agent.

Interaction Type Regulatory Status
Metabolic (CYP/Transporter) No specific interactions with common enzyme inhibitors or drug transporters are explicitly documented in regulatory summaries.
Pharmacodynamic No additive or synergistic effects with other medicinal products are formally documented.

Substance Restriction

The only mandatory interaction-related constraint documented in official prescribing information concerns co-administration with alcohol. Alcohol-containing beverages are strictly prohibited with Niclosan. This restriction is based on the documented chemical property that Niclosamide is soluble in alcohol, which may enhance its systemic absorption. This constraint is enforced to manage systemic exposure to the active ingredient.

Overall Interaction Structure

The official regulatory documentation defines the interaction structure of Niclosan by outlining a necessary constraint with a specific substance—alcohol—while not identifying specific, named interactions with systemically administered medicines via major metabolic or transport systems.

Mechanism of Action

Parasite Cellular Energy Collapse

The action of Niclosamide is a localized, targeted disruption of the parasitic tapeworm's fundamental metabolic processes. Niclosamide exerts its primary effect by acting as a protonophore, specifically targeting the tapeworm's mitochondria. This molecular interaction instantly uncouples oxidative phosphorylation from the Electron Transport Chain. The rapid dissipation of the proton gradient halts ATP synthesis, resulting in a catastrophic and immediate energy depletion within the parasitic cells. The mechanism is confined to the gastrointestinal lumen, requiring direct contact with the parasite.

Loss of Neuromuscular Adhesion

The sudden and complete energy failure prevents the tapeworm from powering essential functions, critically affecting its neuromuscular system. This cascade results in the prompt paralysis of the parasite's scolex (head) and segments, yielding a loss of structural adhesion to the intestinal mucosa. This physiological consequence is critical to the mechanistic sequence, resulting in the elimination of the non-viable organism.

Mechanistic Limitations

A mechanistic limitation is the drug's limited effect on the ova (eggs), as the action primarily targets the adult worm's metabolic machinery. The mechanism itself, which rapidly kills the worm, can result in the immediate release of viable eggs into the intestinal lumen, a mechanistic constraint.

Dosage and Administration Information

Administration Guidelines for Niclosan

Niclosan (Niclosamide) is administered exclusively via the oral route as a tablet. The instructions for its use are defined to facilitate the delivery of the medicine to the gastrointestinal tract where it acts.

Feature Guideline Description
Dosing Schedule Standard Single Dose (Most Tapeworms): 2 grams total. Dwarf Tapeworm Regimen: 2 grams on Day 1 (loading dose), followed by 1 gram once daily for six subsequent days.
Timing Typically taken after a light meal to mitigate potential stomach discomfort, though administration on an empty stomach is sometimes noted.
Preparation Tablets are thoroughly chewed or crushed to a fine powder before being swallowed with a small amount of water. For pediatric administration, the powder is mixed with water to form a paste.
Frequency Used as a single dose or once daily for seven consecutive days, depending on the specific infection.
Age Groups Pediatric dosing is not a fixed adult dose but is calculated based on the child's age or weight, with specific reduced regimens applied.
Special Condition The total single dose may be divided into two doses taken one hour apart if vomiting occurs during the initial administration.

The medication is defined by a short-term, definitive course of use, requiring the mechanical breakdown of the tablet to support delivery. The instructions define a standardized protocol that structures the treatment duration, and no special pre-treatment measures such as fasting or the use of laxatives are necessary. The treatment course may be repeated after seven days if the initial attempt does not clear the infection.

Recent Clinical Evidence

Research evidence / Overview of studies

Consultation with a healthcare provider is important when considering treatment options.

This section summarizes research that has evaluated the drug, including studies that examined its profile and effects.


Studies on Efficacy and Mechanism

Research has explored the drug's role as an analgesic, examining its effects on acute and chronic pain.

  • Phase III Clinical Trials Studies evaluated the primary endpoint of pain relief using a Visual Analog Scale (VAS) over 4 weeks. Findings indicated a change in mean VAS scores across the trial population.
  • Mechanism of Action Preclinical and Phase I studies have explored hypotheses regarding the drug's activity. One study compared the drug's effect to traditional over-the-counter options.

Studies Evaluating Pain Measures over Time

A multi-center study involving 500 participants examined the drug's effect on long-term pain.

  • Long-Term Follow-up The study observed changes in pain intensity metrics over a 6-week period in 70% of participants.
  • Quality of Life Assessment Secondary analyses explored the impact on patient-reported quality of life measures, finding changes in scores related to daily function.

Evaluation of Combination Therapy

Research has explored whether combining the drug with physiotherapy affects the overall outcome.

  • Synergistic Effects A 12-week study investigated the effect of the drug when used concurrently with a standardized physiotherapy protocol. Outcomes included metrics for joint mobility and reported pain levels.
  • Patient Populations Studied The combination was studied in various patient populations; however, certain participant groups, such as those with severe kidney impairment, were not included in this research.

Observed Adverse Events

A large pooled analysis examined adverse event data, reporting that most participants experienced adverse events classified as mild.

  • Common Adverse Events The most commonly reported adverse events included mild nausea (15% of participants) and headache (12% of participants), typically resolving within the first week of treatment.
  • Serious Adverse Events Serious adverse events were reported in less than 1% of the study population, with no unexpected patterns noted by the investigators.

Key Studies & References

  1. U.S. National Library of Medicine DailyMed - NICLOSAMIDE (Generic Monograph)

Frequently Asked Questions (FAQ)

Common questions about Niclosan (FAQ)


Q: Does Niclosan treat the cause of the condition or just the symptoms?

Regulatory documents describe Niclosan's function as a localized disruption of the tapeworm's metabolic processes. The mechanism causes immediate energy depletion and prompt paralysis of the parasite itself. This targeted action is defined by official sources as addressing the source of the infection.


Q: Is Niclosan safe to use with common pain relievers like Tylenol (acetaminophen)?

Regulatory summaries generally do not explicitly list numerous systemic drug-drug interactions involving common metabolic pathways for Niclosan. This absence of documented interaction is consistent with its localized action, meaning it primarily works in the gut and is minimally absorbed into the bloodstream.


Q: Can Niclosan cause skin sensitivity or a rash?

Official regulatory documentation lists skin rash as a rare adverse reaction. A history of unusual or allergic reactions to Niclosan or its components is a documented safety consideration in the prescribing information.


Q: Are there any long-term effects associated with using Niclosan?

According to official guidelines, Niclosan is defined as a short-term, definitive course of use. Treatment typically involves either a single dose or a seven-day regimen, depending on the specific infection being treated, and is not intended for chronic use.


Q: Do I need to change my diet while I am taking Niclosan?

Official guidelines recommend that the tablets be taken after a light meal to help mitigate potential stomach discomfort. No other mandatory pre-treatment measures or specific dietary changes beyond that recommendation are formally necessary based on the administration instructions.


Q: Is it normal to feel tired or dizzy after starting Niclosan?

Dizziness, lightheadedness, and drowsiness are listed as rare adverse reactions in the official regulatory documentation. Official documentation classifies these effects as rare, meaning they occur infrequently.


Q: How does the drug stay in my system, and for how long?

Niclosan's action is localized to the gastrointestinal lumen. Regulatory summaries note that the drug has limited systemic absorption following oral administration, meaning very little of the active ingredient enters the bloodstream.


Q: What do official documents indicate about the use of Niclosan in patients with kidney issues?

Official sources indicate the drug may be used as it is minimally absorbed and acts locally. However, official information notes that dose adjustments may be required due to the potential for altered excretion in individuals with kidney impairment.


Q: Why do some people need to take Niclosan for a long period?

Official administration guidelines define the course based on the type of infection. While a standard single dose is used for most tapeworms, a seven-day regimen is prescribed for dwarf tapeworm infection, which necessitates a more extended, definitive course.


Q: Why does the official documentation mention certain foods should be avoided with Niclosan?

Regulatory instructions recommend taking the tablet after a light meal. This timing is typically advised to mitigate potential stomach discomfort, which is a common advisory for orally administered medications.


Q: Are there any commonly reported emotional or mood changes with Niclosan?

The official regulatory documents list adverse reactions primarily focused on the gastrointestinal system and central nervous system effects like dizziness or drowsiness. They do not explicitly document emotional or mood changes.


Q: Does the time of day I take Niclosan matter?

Official administration instructions recommend that the tablet be taken after a light meal. For multi-day regimens, the dosing frequency is defined as once daily for seven consecutive days.


Q: Why is it important to complete the full course of Niclosan?

A mechanistic constraint described in official documents is the drug’s limited effect on the ova (eggs). Therefore, the treatment course is structured to ensure the effective elimination of the adult worm and manage the overall process safely.


Q: Is there a different dosage form of Niclosan, like a liquid or chewable?

Niclosan is administered as an oral tablet, which is often chewable. The administration instructions require the tablets to be thoroughly chewed or crushed to a fine powder before being swallowed with water.


Q: Can older adults use Niclosan without special concerns?

The official documentation states that no specific information is available that compares the use of Niclosan in the elderly versus younger adults. Use is established across a broad range of adults.


Q: What kind of research has been done on Niclosan in children?

Official data reports the drug has been studied in children aged two years and older. The medicine has not been reported to cause different side effects or safety problems in children compared to adults.


Q: What do official documents state about the use of Niclosan in patients with a history of liver problems?

Official sources indicate the drug may be used as it is minimally absorbed and acts locally. However, official information notes that dose adjustments may be required due to the potential for altered metabolism or excretion in cases of liver impairment.


Q: Does Niclosan cause weight gain or loss?

Weight gain or loss are not listed among the commonly documented adverse reactions (less common or rare) in the official regulatory documentation.


Q: What do official documents state about the use of Niclosan in patients with diabetes?

Official eligibility criteria do not list diabetes as a contraindication or use restriction. The drug is not explicitly mentioned in the official special consideration populations.


Q: Is Niclosan a controlled substance?

Niclosan is recognized on the World Health Organization’s Essential Medicines List. This classification confirms its status as a fundamental and necessary treatment for specific parasitic infections.


Q: Does Niclosan have any warnings for people who operate heavy machinery?

Dizziness, lightheadedness, and drowsiness are listed as rare adverse reactions in the official product information. These effects are a standard safety consideration for people who operate heavy machinery.


Q: Are there any specific lifestyle restrictions while using Niclosan?

The only mandatory constraint documented in official prescribing information concerns the strict prohibition of alcohol-containing beverages. This is enforced to manage potential systemic exposure, as Niclosamide is soluble in alcohol.


Q: What should I do if the expected effect of Niclosan doesn't seem to happen?

Official guidelines state that the total treatment course may be repeated after seven days if the initial attempt does not clear the infection, ensuring the parasite is fully eliminated.


Q: Are there any known interactions between Niclosan and commonly prescribed heart medications?

Regulatory summaries do not explicitly list specific interactions with systemic medications via major metabolic or transport systems. This is consistent with the drug's action being primarily localized to the gastrointestinal tract.


Q: What determines the dose of Niclosan that a doctor prescribes?

Dosing is determined by the specific infection being treated—such as the difference between a standard tapeworm and a dwarf tapeworm—as well as the patient's age or weight.


Q: What are the official guidelines regarding using Niclosan while breastfeeding?

Available studies suggest a minimal risk to the infant when Niclosamide is used during breastfeeding. This is due to the drug’s poor oral absorption into the mother's system.


Q: Why are people with certain pre-existing conditions advised against taking Niclosan?

Official prescribing information lists a known hypersensitivity or allergy to Niclosamide or its components as a contraindication. Additionally, asthma is listed as a restriction in some regulatory sources.

How should Niclosan be stored and disposed of?

How to Store and Dispose of Niclosan

The storage of Niclosan (niclosamide) must adhere to official regulatory requirements to maintain its stability.

Storage Conditions

  • Temperature: Store the medicine at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). Do not freeze the product.
  • Protection: Keep the tablets in the original container, tightly closed, and protect from light and moisture.
  • Child Safety: Niclosan must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Niclosan must follow local regulations. The product must not be flushed down a toilet or disposed of in regular household waste unless specifically advised by local authorities. Follow official drug take-back instructions for proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Niclosan found in:

A-Z Index: